Use of CCL1 in therapy
A method of treating a medical condition in which suppression of effector T cells is beneficial in a subject in need thereof is disclosed. The method comprising administering to the subject a therapeutically effective amount of a CCL1 polypeptide, thereby treating the medical condition in the subject.
1. A method of treating an inflammatory bowel disease (IBD) in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a CCL1 fusion polypeptide comprising SEQ NO: 8 and an Fc constant region of an immunoglobulin, thereby treating the IBD in the subject in need thereof.
2. The method of claim 1 , wherein said CCL1 fusion polypeptide is as set forth in SEQ ID NO: 10.
3. The method of claim 1 , wherein the IBD is selected from group consisting of colitis and Crohn's disease.